Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

People's Hospital of Xinjiang Uygur Autonomous Region

25. května 2026 aktualizováno: Xiumin Zhang, People's Hospital of Xinjiang Uygur Autonomous Region

Objective: To evaluate the impact of enhanced recovery after surgery (ERAS)-based nursing intervention on venous thromboembolism (VTE) and lymphedema after radical hysterectomy for cervical cancer.

Methods: In this prospective randomized controlled trial, 160 patients scheduled for radical hysterectomy during September 2022-September 2024 were randomized to an ERAS group (n = 80) or a control group (n = 80). The control group received conventional perioperative care, while the ERAS group received a multimodal perioperative care protocol. Primary outcomes were the 6-month incidence of VTE and lower limb lymphedema. Secondary outcomes included recovery indicators, inflammatory and coagulation markers, quality of life [QoL; assessed by the Quality of Life Questionnaire-Core 30 (QLQ-C30)], and nursing satisfaction.

Přehled studie

Typ studie

Intervenční

Zápis (Aktuální)

160

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Xinjiang Uygur Autonomous Region
      • Ürümqi, Xinjiang Uygur Autonomous Region, Čína, 830000
        • People's Hospital of Xinjiang Uygur Autonomous Region

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • . Pathologically confirmed cervical cancer (FIGO 2018) 2. Age 18-70 years 3. First-time radical hysterectomy 4. ASA physical status class I-II 5. Perioperative anticoagulant prophylaxis per hospital standards 6. Provision of informed consent

Exclusion Criteria:

  • 1. Pre-existing lower extremity DVT, lymphedema, or severe varicose veins 2. Severe cardiac, hepatic, or renal dysfunction or coagulation disorders 3. History of psychiatric illness or communication barriers 4. Pregnant or lactating women

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Podpůrná péče
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Žádný zásah: Conventional Perioperative Care
The control group received conventional perioperative care. This included routine preoperative education, fasting for 12 hours and no oral intake for 6 hours preoperatively, standard intraoperative fluid administration, postoperative patient-controlled analgesia pump, ambulation guided by traditional instructions (typically 1-2 days postoperatively), and initiation of liquid diet after passing flatus.
Experimentální: ERAS Multimodal Pathway

In addition to conventional care, the ERAS group received a comprehensive intervention protocol based on ERAS principles, implemented by a dedicated ERAS nursing team. Details are as follows:

Preoperative interventions: (1) Enhanced education and prehabilitation: Detailed explanation of the ERAS pathway, VTE and lymphedema prevention using graphics and videos. Instruction on ankle pump exercises and quadriceps isometric contractions. (2) Nutritional support: Nutritional risk assessment and provision of oral nutritional supplements if necessary. (3) Fasting management: No solid food for 6 hours, clear oral fluids (e.g., 200 mL of 10% glucose solution) allowed up to 2 hours preoperatively.

Intraoperative interventions: (1) Thermoregulation: Use of forced-air warming blankets and fluid warmers to maintain core temperature > 36°C. (2) Restrictive fluid management: Goal-directed fluid therapy to avoid excessive infusion. (3) Minimally invasive and meticulous surgery: Encouragement of lapar

In addition to conventional care, the ERAS group received a comprehensive intervention protocol based on ERAS principles, implemented by a dedicated ERAS nursing team. Details are as follows:

Preoperative interventions: (1) Enhanced education and prehabilitation: Detailed explanation of the ERAS pathway, VTE and lymphedema prevention using graphics and videos. Instruction on ankle pump exercises and quadriceps isometric contractions. (2) Nutritional support: Nutritional risk assessment and provision of oral nutritional supplements if necessary. (3) Fasting management: No solid food for 6 hours, clear oral fluids (e.g., 200 mL of 10% glucose solution) allowed up to 2 hours preoperatively.

Intraoperative interventions: (1) Thermoregulation: Use of forced-air warming blankets and fluid warmers to maintain core temperature > 36°C. (2) Restrictive fluid management: Goal-directed fluid therapy to avoid excessive infusion. (3) Minimally invasive and meticulous surgery: Encouragement of laparo

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of Postoperative Venous Thromboembolism (VTE)
Časové okno: 6 months after surgery
Composite incidence of deep vein thrombosis (DVT) of the lower extremities and pulmonary embolism (PE). DVT is diagnosed by bilateral lower extremity venous color Doppler ultrasonography performed on postoperative day 3, before discharge, and at 1, 3, and 6 months postoperatively or when clinically indicated. PE is evaluated by computed tomography pulmonary angiography (CTPA) when clinically suspected.
6 months after surgery

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of Postoperative Lower Limb Lymphedema
Časové okno: 6 months after surgery
Diagnosis based on International Society of Lymphology criteria (Grade I: pitting edema relieved by elevation; Grade II: non-pitting edema with tissue fibrosis; Grade III: elephantiasis). Measured by bilateral calf circumference (thickest point) and thigh circumference (15 cm above patella).
6 months after surgery
Time to First Flatus
Časové okno: Within 14 days after surgery (typically hours to days)
Number of hours from surgery completion to first passage of flatus, indicating recovery of gastrointestinal function.
Within 14 days after surgery (typically hours to days)
Time to First Defecation
Časové okno: Within 14 days after surgery (typically days)
Number of hours from surgery completion to first bowel movement.
Within 14 days after surgery (typically days)
Time to First Ambulation
Časové okno: Within 7 days after surgery
Number of days from surgery completion to the first time the patient walks independently (assisted or unassisted) outside the bed area.
Within 7 days after surgery
Postoperative Length of Hospital Stay
Časové okno: At hospital discharge, assessed up to 4 weeks postoperatively
Total number of days from the date of surgery to the date of hospital discharge.
At hospital discharge, assessed up to 4 weeks postoperatively
Change in C-Reactive Protein (CRP)
Časové okno: Preoperative (baseline) vs. Postoperative day 3
Change in serum C-reactive protein (CRP) measured from fasting blood samples, reported in mg/L.
Preoperative (baseline) vs. Postoperative day 3
Change in D-Dimer (D-D)
Časové okno: Preoperative (baseline) vs. Postoperative day 3
Change in plasma D-dimer (D-D) measured from fasting blood samples, reported in mg/L.
Preoperative (baseline) vs. Postoperative day 3
Change in Platelet Count (PLT)
Časové okno: Preoperative (baseline) vs. Postoperative day 3
Change in platelet count (PLT) measured from complete blood count, reported in ×10⁹/L.
Preoperative (baseline) vs. Postoperative day 3
Change in Global Health Status / Quality of Life (QLQ-C30)
Časové okno: Preoperative (baseline) vs. 6 months postoperatively
Change in the Global Health Status / Quality of Life subscale score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Minimum value: 0. Maximum value: 100. Higher scores indicate better quality of life.
Preoperative (baseline) vs. 6 months postoperatively
Nursing Satisfaction
Časové okno: At hospital discharge (postoperative day 7 to day 15)
Measured by the Newcastle Satisfaction with Nursing Scale (NSNS). Categorized as: highly satisfied, moderately satisfied, or not satisfied. Overall satisfaction rate = (highly satisfied + moderately satisfied) / total patients × 100%.
At hospital discharge (postoperative day 7 to day 15)
Change in White Blood Cell Count (WBC)
Časové okno: Preoperative (baseline) vs. Postoperative day 3
Change in white blood cell count (WBC) measured from fasting blood samples, reported in ×10⁹/L.
Preoperative (baseline) vs. Postoperative day 3
Change in Prothrombin Time (PT)
Časové okno: Preoperative (baseline) vs. Postoperative day 3
Change in prothrombin time (PT) measured from fasting blood samples, reported in seconds.
Preoperative (baseline) vs. Postoperative day 3
Change in Hemoglobin (Hb)
Časové okno: Preoperative (baseline) vs. Postoperative day 3
Change in hemoglobin (Hb) measured from complete blood count, reported in g/L.
Preoperative (baseline) vs. Postoperative day 3
Change in Functional Scales (QLQ-C30)
Časové okno: Preoperative (baseline) vs. 6 months postoperatively
Change in the Functional Scales composite score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Minimum value: 0. Maximum value: 100. Higher scores indicate better functional status.
Preoperative (baseline) vs. 6 months postoperatively
Change in Symptom Scales (QLQ-C30)
Časové okno: Preoperative (baseline) vs. 6 months postoperatively
Change in the Symptom Scales composite score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Minimum value: 0. Maximum value: 100. Higher scores indicate worse symptom burden.
Preoperative (baseline) vs. 6 months postoperatively
Change in Single Items (QLQ-C30)
Časové okno: Preoperative (baseline) vs. 6 months postoperatively
Change in the Single Items score (including dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Minimum value: 0. Maximum value: 100. Higher scores indicate worse symptom burden or greater financial difficulty.
Preoperative (baseline) vs. 6 months postoperatively
Change in Total Score (QLQ-C30)
Časové okno: Preoperative (baseline) vs. 6 months postoperatively
Change in the total score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Minimum value: 0. Maximum value: 100. Higher scores indicate better overall quality of life.
Preoperative (baseline) vs. 6 months postoperatively

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

5. září 2022

Primární dokončení (Aktuální)

17. září 2024

Dokončení studie (Aktuální)

26. září 2024

Termíny zápisu do studia

První předloženo

19. května 2026

První předloženo, které splnilo kritéria kontroly kvality

25. května 2026

První zveřejněno (Aktuální)

29. května 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

29. května 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

25. května 2026

Naposledy ověřeno

1. května 2026

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Rakovina děložního hrdla

Klinické studie na ERAS group

Předplatit